Invention Grant
- Patent Title: Galectin-3 plasmapheresis therapy
-
Application No.: US16988679Application Date: 2020-08-09
-
Publication No.: US12109346B2Publication Date: 2024-10-08
- Inventor: Isaac Eliaz
- Applicant: ELIAZ THERAPEUTICS, INC
- Applicant Address: US CA Sebastopol
- Assignee: Eliaz Therapeutics, Inc.
- Current Assignee: Eliaz Therapeutics, Inc.
- Current Assignee Address: US CA Sebastopol
- Agency: The Kelber Law Group
- Agent Steven B. Kelber
- Main IPC: A61M1/36
- IPC: A61M1/36 ; A61K35/14 ; A61K35/16 ; A61K35/17 ; A61K39/395 ; A61M1/34 ; A61N5/06

Abstract:
A system and method for the practice of apheresis employs modules in the system which can be selected for a particular patient to treat particular situations or combinations of difficulties. In one example, Gal-3 mediates a large number of body reactions, and is an effective protector of tumor microenvironments and the like, as well inflammation driver. Removal of Gal-3 may make antic-cancer treatments, like photopheresis and TNF administration more effective. Separate modules, such as one for photopheresis and one for TNF receptor removal, may be combined with a module for the reduction of Gal-3, to render the combination of treatments each more effective than if administered alone.
Public/Granted literature
- US20210001032A1 GALECTIN-3 PLASMAPHERESIS THERAPY Public/Granted day:2021-01-07
Information query
IPC分类: